NDC product
Exelon
NDC 0078-0503 · Novartis Pharmaceuticals Corporation
Key facts
| Product NDC | 0078-0503 |
|---|---|
| Proprietary name | Exelon |
| Nonproprietary name | rivastigmine |
| Substances | RIVASTIGMINE |
| Dosage form | PATCH, EXTENDED RELEASE |
| Route | TRANSDERMAL |
| Labeler | Novartis Pharmaceuticals Corporation |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA022083 |
| Pharmacologic classes | Cholinesterase Inhibitor [EPC], Cholinesterase Inhibitors [MoA] |
| Marketing start | Jul 6, 2007 |
| Marketing end | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory